FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2772853899> ?p ?o ?g. }

• W2772853899 abstract "In 2008, the multikinase inhibitor Sorafenib consistently proved to extend the survival of patients with Hepatocellular Carcinoma (HCC) that were treated in the advanced stage and had a good liver function, and it became the first agent to be specifically approved for this indication (ref). Although Sorafenib was a paradigm shift in the field, systemic therapy of HCC remains a major unmet need. The mechanism of action of Sorafenib is still poorly understood and the same is true for the mechanism of resistance after initial response, which usually reveals as disease stabilization for a few months. Molecular biomarkers predicting response and resistance to Sorafenib are also hardly defined. Furthermore, all subsequent novel targeted agents or regimens tested in large randomized controlled trials both in the first-line and second-line setting have been unable to reach or improve the magnitude of benefit obtained with Sorafenib. Strategies under study have included the blockade of other pro-angiogenic signals such as the FGFR pathway using Brivanib, proliferative signals such as the EGFR pathway using Erlotinib, or cell growth, proliferation, angiogenesis and apoptosis signals arising from the PI3K-Akt-mTOR pathway using Everolimus. The relevance of targeting these pathways is still not completely understood since biomarker data have not been reported, including EGFR and FGFR expression in tumor specimens. Besides, a number of trials have definitively shown the lack of efficacy of Doxorubicin, used for decades as a systemic therapy for HCC patients without formal scientific evidence. And no survival benefit was proven for combination chemotherapy based on 5-fluorouracil and oxaliplatin. The door was then opened to a more focused approach in which only patients with an altered targeted pathway are deemed candidates for a given agent. The anticancer activity of the c-met tyrosine kinase inhibitor Tivantinib was suggested in a randomized, placebo-controlled trial in the second-line setting where patients with high c-met expression survived significantly longer if they received Tivantinib. Patient enrichment based on molecular targets has been incorporated into the clinical development of other agents such as a monoclonal antibody that binds to glypican-3 or Refametinib a tyrosine kinase inhibitor that targets the MAPK (Ras-Raf-MEK-ERK) pathway. Agents targeting novel signaling pathways including TGF-β and FGF19, but also less explored pathways such as Wntβ-catenin, Hedgehog or Notch are being studied for the treatment of HCC. We will soon learn whether or not this more selective approach translates into positive results. Identification of driver molecular events in an individual patient using markers from tumor biopsies has proven successful in other tumors including breast or lung cancer. However, the reliability of this strategy has been challenged by studies showing intratumoural heterogeneity in various malignancies at advanced stages. HCC needs to be explored in this regard. Citation Format: Bruno Sangro. Targeted therapies for hepatocellular carcinoma [abstract]. In: Proceedings of the AACR International Conference: New Frontiers in Cancer Research; 2017 Jan 18-22; Cape Town, South Africa. Philadelphia (PA): AACR; Cancer Res 2017;77(22 Suppl):Abstract nr IA25." @default.
• W2772853899 created "2017-12-22" @default.
• W2772853899 creator A5085766415 @default.
• W2772853899 date "2017-11-14" @default.
• W2772853899 modified "2023-09-27" @default.
• W2772853899 title "Abstract IA25: Targeted therapies for hepatocellular carcinoma" @default.
• W2772853899 doi "https://doi.org/10.1158/1538-7445.newfront17-ia25" @default.
• W2772853899 hasPublicationYear "2017" @default.
• W2772853899 type Work @default.
• W2772853899 sameAs 2772853899 @default.
• W2772853899 citedByCount "0" @default.
• W2772853899 crossrefType "proceedings-article" @default.
• W2772853899 hasAuthorship W2772853899A5085766415 @default.
• W2772853899 hasBestOaLocation W27728538991 @default.
• W2772853899 hasConcept C121608353 @default.
• W2772853899 hasConcept C126322002 @default.
• W2772853899 hasConcept C143998085 @default.
• W2772853899 hasConcept C185592680 @default.
• W2772853899 hasConcept C2778019345 @default.
• W2772853899 hasConcept C2778087573 @default.
• W2772853899 hasConcept C2778695046 @default.
• W2772853899 hasConcept C2779438470 @default.
• W2772853899 hasConcept C2779490328 @default.
• W2772853899 hasConcept C2779699572 @default.
• W2772853899 hasConcept C2780394083 @default.
• W2772853899 hasConcept C2781230642 @default.
• W2772853899 hasConcept C502942594 @default.
• W2772853899 hasConcept C535046627 @default.
• W2772853899 hasConcept C55493867 @default.
• W2772853899 hasConcept C62478195 @default.
• W2772853899 hasConcept C71924100 @default.
• W2772853899 hasConcept C86554907 @default.
• W2772853899 hasConceptScore W2772853899C121608353 @default.
• W2772853899 hasConceptScore W2772853899C126322002 @default.
• W2772853899 hasConceptScore W2772853899C143998085 @default.
• W2772853899 hasConceptScore W2772853899C185592680 @default.
• W2772853899 hasConceptScore W2772853899C2778019345 @default.
• W2772853899 hasConceptScore W2772853899C2778087573 @default.
• W2772853899 hasConceptScore W2772853899C2778695046 @default.
• W2772853899 hasConceptScore W2772853899C2779438470 @default.
• W2772853899 hasConceptScore W2772853899C2779490328 @default.
• W2772853899 hasConceptScore W2772853899C2779699572 @default.
• W2772853899 hasConceptScore W2772853899C2780394083 @default.
• W2772853899 hasConceptScore W2772853899C2781230642 @default.
• W2772853899 hasConceptScore W2772853899C502942594 @default.
• W2772853899 hasConceptScore W2772853899C535046627 @default.
• W2772853899 hasConceptScore W2772853899C55493867 @default.
• W2772853899 hasConceptScore W2772853899C62478195 @default.
• W2772853899 hasConceptScore W2772853899C71924100 @default.
• W2772853899 hasConceptScore W2772853899C86554907 @default.
• W2772853899 hasLocation W27728538991 @default.
• W2772853899 hasOpenAccess W2772853899 @default.
• W2772853899 hasPrimaryLocation W27728538991 @default.
• W2772853899 hasRelatedWork W1534283717 @default.
• W2772853899 hasRelatedWork W1756205400 @default.
• W2772853899 hasRelatedWork W1770529458 @default.
• W2772853899 hasRelatedWork W1842084427 @default.
• W2772853899 hasRelatedWork W1978299522 @default.
• W2772853899 hasRelatedWork W1985569200 @default.
• W2772853899 hasRelatedWork W1995684830 @default.
• W2772853899 hasRelatedWork W2000035904 @default.
• W2772853899 hasRelatedWork W2032242790 @default.
• W2772853899 hasRelatedWork W2034024252 @default.
• W2772853899 hasRelatedWork W2079052314 @default.
• W2772853899 hasRelatedWork W2089444383 @default.
• W2772853899 hasRelatedWork W2126451706 @default.
• W2772853899 hasRelatedWork W2150817352 @default.
• W2772853899 hasRelatedWork W2216641432 @default.
• W2772853899 hasRelatedWork W2330682807 @default.
• W2772853899 hasRelatedWork W2883647456 @default.
• W2772853899 hasRelatedWork W2979105643 @default.
• W2772853899 hasRelatedWork W2999612493 @default.
• W2772853899 hasRelatedWork W2741550963 @default.
• W2772853899 isParatext "false" @default.
• W2772853899 isRetracted "false" @default.
• W2772853899 magId "2772853899" @default.
• W2772853899 workType "article" @default.